The Next Generation of NGS; What's Missing and What's Next
Conference Recording Sep 30, 2013
About the Speaker
Jonathan is the inventor of QuantuMDx’s proprietary sequencing technologies. A molecular geneticist by training, he began his career working in pathology laboratories in the UK. QuantuMDx has now grown to >35 people, with a research base in Newcastle, UK and offices in USA and Singapore. The technology is in an alpha format and a handheld beta device will be available for trials in late 2013.
The DNA sequencing field has seen dramatic advances since the first draft of the human genome was published, with companies reporting ever faster and cheaper methods. However, despite the race to attain the $1000 genome producing a plethora of exciting technologies, CE is still being routinely used for targeted clinical sequencing for genetic testing and drug resistance testing for infectious disease. QuantuMDx is developing two sequencing technologies to address this; a portable, handheld DNA sequencing device for PGx and infectious disease applications, to provide an alternative to slow and relatively expensive CE DNA sequencing and a "LastGen 2.0" technology to take on Nanopore sequencing head on, dubbed, T2T (Telomere to Telomere).